A short overview of CRISPR-Cas technology and its application in viral disease control
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) together with CRISPR-associated (Cas) proteins have catalysed a revolution in genetic engineering. Native CRISPR-Cas systems exist in many bacteria and archaea where they provide an adaptive immune response through sequence-specific degradation of an invading pathogen’s genome. This system has been reconfigured for use in genome editing, drug development, gene expression regulation, diagnostics, the prevention and treatment of cancers, and the treatment of genetic and infectious diseases. In recent years, CRISPR-Cas systems have been used in the diagnosis and control of viral diseases, for example, CRISPR-Cas12/13 coupled with new amplification techniques to improve the specificity of sequence-specific fluorescent probe detection. Importantly, CRISPR applications are both sensitive and specific and usually only require commonly available lab equipment. Unlike the canonical Cas9 which is guided to double-stranded DNA sites of interest, Cas13 systems target RNA sequences and thus can be employed in strategies directed against RNA viruses or for transcriptional silencing. Many challenges remain for these approach, including issues with specificity and the requirement for better mammalian delivery systems. In this review, we summarize the applications of CRISPR-Cas systems in controlling mammalian viral infections. Following necessary improvements, it is expected that CRISPR-Cas systems will be used effectively for such applications in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673 · cited 2×
“In addition, several enhanced fidelity variants of SpCas9 such as eSpCas9 (1.1), SpCas9-HF1, and HeFSpCas9 were produced by rational design to increase on-target editing activity and improve intrinsic SpCas9 specificity (Chen et al. 2017; Kleinstiver et al. 2016; Kulcsár et al. 2017).”
BackgroundInfluentialCRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563 · cited 2×
“This maturation is performed by Cas proteins and/or cellular ribonucleases depending on the given CRISPR-Cas type (Deltcheva et al. 2011; Reeks et al. 2013).”
BackgroundIshino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.12.5429-5433.1987 · Cited by 2,421
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
CRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029 · cited 2×
“…knockdown RNA editing Regulation of gene expression Nucleic acid detection dsDNA, double-stranded DNA; ssRNA, single-stranded RNA; PAM, protospacer adjacent motif; PFS, protospacer-flanking sequence were based on protein–DNA recognition (Doetschman and Georgieva 2017; Jiang and Doudna 2017).”
BackgroundMali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752 · cited 2×
“Since the first successful use of Streptococcus pyogenes Cas9 (SpCas9) for eukaryotic genome engineering, the CRISPR-Cas9 system remains the most widely adopted RNA-guided DNA targeting platform for genome editing (Cong et al. 2013; Jinek et al. 2012; Mali et al. 2013b).”
BackgroundEngineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624 · cited 1×
“The first SpCas9 mutants reported to target altered PAM sites with improved activity were SpCas9-EQR, SpCas9-VQR and, SpCas9-VRER (Kleinstiver et al. 2015).”
BackgroundDiversity, classification and evolution of CRISPR-Cas systems
Koonin, E. V., Makarova, K. S., & Zhang, F. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.008 · Cited by 1,423 · cited 1×
“In addition to eukaryotic RNA interference (RNAi) and prokaryotic Argonaute-based systems, Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated proteins (CRISPR-Cas) systems utilize nucleic acid base-pairing to suppress or destroy genetic targets (Koonin et al. 2017).”
BackgroundEnhanced proofreading governs CRISPR-Cas9 targeting accuracy
Chen, J. S., Dagdas, Y. S., Kleinstiver, B. P., Welch, M. M., Sousa, A. A., Harrington, L. B., Sternberg, S. H., Joung, J. K., Yildiz, A., & Doudna, J. A. (2017) · Nature · doi:10.1038/nature24268 · Cited by 1,168 · cited 2×
“1), SpCas9-HF1, and HeFSpCas9 were produced by rational design to increase on-target editing activity and improve intrinsic SpCas9 specificity (Chen et al. 2017; Kleinstiver et al. 2016; Kulcsár et al. 2017).”
BackgroundTranscriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018) · Cell · doi:10.1016/j.cell.2018.02.033 · Cited by 1,164
Cited by
Current Bioinformatics Tools to Optimize CRISPR/Cas9 Experiments to Reduce Off-Target Effects
Naeem, M., & Alkhnbashi, O. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076261 · Cited by 70
Lai, M., Maori, E., Quaranta, P., Matteoli, G., Maggi, F., Sgarbanti, M., Crucitta, S., Pacini, S., Turriziani, O., Antonelli, G., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01358-21 · Cited by 28
Sharma, K. K., Palakolanu, S. R., Bhattacharya, J., Shankhapal, A. R., & Bhatnagar-Mathur, P. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.999207 · Cited by 24
Metadata
- Authors
- Ghorbani, A., Hadifar, S., Salari, R., Izadpanah, K., Burmistrz, M., Afsharifar, A., Eskandari, M. H., Niazi, A., Denes, C. E., & Neely, G. G.
- Venue
- Transgenic Research
- Published
- 2021-04-08
- Volume
- 30
- Issue
- 3
- Pages
- 221-238
- ISSN
- 0962-8819 (ISSN-L)
- 1573-9368
- OpenAlex
- W3143090907
- Cited by
- 36
- References
- 22
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A short overview of CRISPR-Cas technology and its application in viral disease control. https://app.cochat.ai/papers/10.1007/s11248-021-00247-w
- The paper
- Ghorbani, A., Hadifar, S., Salari, R., Izadpanah, K., Burmistrz, M., Afsharifar, A., Eskandari, M. H., Niazi, A., Denes, C. E., & Neely, G. G. (2021). A short overview of CRISPR-Cas technology and its application in viral disease control. Transgenic Research. https://doi.org/10.1007/s11248-021-00247-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.